1. Home
  2. Research
  3. Centers & Labs
  4. RIKEN Center for Integrative Medical Sciences

RIKEN Center for Integrative Medical Sciences Laboratory for Pharmacogenomics

Team Leader: Taisei Mushiroda (Ph.D.)

Research Summary

Taisei  Mushiroda(Ph.D.)

The Laboratory for Pharmacogenetics aims to identify genes associated with drug efficacy and adverse drug reactions, leading to the establishment of personalized therapeutics based on pharmacogenomics.
A combination of genetic variations and environmental differences defines unique human characteristics, including individual responsiveness (effectiveness and adverse reaction) to drugs. Among several types of genetic variation, single-nucleotide polymorphisms (SNPs) are the most abundant throughout the genome. SNPs have lately received much attention in biomedical fields, because some of them can influence the quality and/or the quantity of particular gene products, and thereby serve as markers of individual risk for adverse drug reactions or susceptibility to complex diseases. We expect the genomic approach, by exploiting an already large collection of SNPs and haplotype maps based on that collection, to revolutionize drug discovery and development, as well as the practice of medicine, within the next 5-10 years. Genetic variations in genes encoding proteins involved in drug metabolism, transport and response are of increasing importance for selecting particular drugs and an optimal dosages to provide the maximum effect and minimal adverse reactions for individual patients. The SNP-based approach makes us confident of achieving one of our goals, which is establishment of 'personalized medicine' that can provide the right drug at the appropriate dose for each individual patient.

Main Research Fields

  • Medicine, Dentistry & Pharmacy


  • Pharmacogenomics
  • Genomic biomarker
  • Drug response
  • Adverse drug reaction
  • Germline genetic testing

Selected Publications

  • 1.Giacomini KM, Yee SW, Mushiroda T, Weinshilboum RM, Ratain MJ, Kubo M.:
    "Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine"
    Nat Rev Drug Discov 16, 1 (2017).
  • 2.Yoshihama T, Hirasawa A, Nomura H, Akahane T, Nanki Y, Yamagami W, Kataoka F, Tominaga E, Susumu N, Mushiroda T, Aoki D.:
    "UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan"
    Jpn J Clin Oncol, 47, 170-4 (2017).
  • 3.Wattanapokayakit S, Mushiroda T, Yanai H, Wichukchinda N, Chuchottawon C, Nedsuwan S, Rojanawiwat A, Denjanta S, Kantima T, Wongyai J, Suwankesawong W, Rungapiromnan W, Kidkeukarun R, Bamrungram W, Chaiwong A, Suvichapanich S, Mahasirimongkol S, Tokunaga K.:
    "NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients"
    Int J Tuberc Lung Dis 20, 1364-9 (2016).
  • 4.Mushiroda T, Yanai H, Yoshiyama T, Sasaki Y, Okumura M, Ogata H, Tokunaga K.:
    "Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients"
    Hum Genome Var 23, 16014 (2016).
  • 5.Fukunaga K, Nakagawa H, Ishikawa T, Kubo M, Mushiroda T.:
    "ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population"
    BMC Genet 17, 79 (2016).
  • 6.Saito T, Ikeda M, Mushiroda T, Ozeki T, Kondo K, Shimasaki A, Kawase K, Hashimoto S, Yamamori H, Yasuda Y, Fujimoto M, Ohi K, Takeda M, Kamatani Y, Numata S, Ohmori T, Ueno S, Makinodan M, Nishihata Y, Kubota M, Kimura T, Kanahara N, Hashimoto N, Fujita K, Nemoto K, Fukao T, Suwa T, Noda T, Yada Y, Takaki M, Kida N, Otsuru T, Murakami M, Takahashi A, Kubo M, Hashimoto R, Iwata N.:
    "Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese Population"
    Biol Psychiatry 80, 636-42 (2016).
  • 7.Low JS, Chin YM, Mushiroda T, Kubo M, Govindasamy GK, Pua KC, Yap YY, Yap LF, Subramaniam SK, Ong CA, Tan TY, Khoo AS; Malaysian NPC Study Group, Ng CC.:
    "A genome wide study of copy number variation associated with nasopharyngeal carcinoma in Malaysian Chinese identifies CNVs at 11q14.3 and 6p21.3 as candidate loci"
    PLoS One 11, e0145774 (2016).
  • 8.Chin YM, Mushiroda T, Takahashi A, Kubo M, Krishnan G, Yap LF, Teo SH, Lim PV, Yap YY, Pua KC, Kamatani N, Nakamura Y, Sam CK, Khoo AS; Malaysian NPC Study Group, Ng CC.:
    "HLA-A SNPs and amino acid variants are associated with nasopharyngeal carcinoma in Malaysian Chinese"
    Int J Cancer 136, 678-87 (2015).
  • 9.Miura Y, Imamura CK, Fukunaga K, Katsuyama Y, Suyama K, Okaneya T, Mushiroda T, Ando Y, Takano T, Tanigawara Y.:
    "Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype"
    BMC Cancer 14, 964 (2014).
  • 10.Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MT, Ambrosone CB, Beckmann MW, Choi JY, Dieudonné AS, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park BW, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wegman P, Wingren S, Wu AH, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE.:
    "CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations"
    Clin Pharmacol Ther 95, 216-27 (2014).

Related Links

Lab Members

Principal investigator

Taisei Mushiroda
Team Leader

Core members

Takeshi Ozeki
Research Scientist
Koya Fukunaga
Research Scientist
Keiko Hikino
Research Associate
Tomoko Yoshihama
Junior Research Associate
Mitsunori Yahata
Technical Staff I
Shoko Higuchi
Technical Staff II
Yuko Ohta
Technical Staff II
Aiko Oono
Technical Staff II
Yuuka Kikuchi
Technical Staff II

Contact Information

1-7-22 Suehiro-cho, Tsurumi-ku,
Yokohama City, Kanagawa,
230-0045, Japan
Tel: +81-(0)45-503-9597
Fax: +81-(0)45-503-9568
Email: mushiroda [at] riken.jp